A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure - Trial NCT06299826
Access comprehensive clinical trial information for NCT06299826 through Pure Global AI's free database. This Phase 2 trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Heart Failure. Target enrollment is 360 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 2
Jun 10, 2024
Nov 24, 2025
Primary Outcome
Cohort A and B: Change from Baseline in Ejection Fraction
Summary
The main purpose of this study is to evaluate the effect of AZD5462 on cardiac function in
 participants with chronic heart failure (HF).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06299826
Non-Device Trial